Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24968263)

  • 1. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
    Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
    PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
    Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
    BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
    Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
    Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Carter JH; Cottrell CE; McNulty SN; Vigh-Conrad KA; Lamp S; Heusel JW; Duncavage EJ
    Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 28835367
    [No Abstract]   [Full Text] [Related]  

  • 6. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
    Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
    Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.
    Lau WM; Teng E; Huang KK; Tan JW; Das K; Zang Z; Chia T; Teh M; Kono K; Yong WP; Shabbir A; Tay A; Phua NS; Tan P; Chan SL; So JBY
    Mol Cancer Ther; 2018 Jan; 17(1):232-242. PubMed ID: 28978722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
    Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
    Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
    Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
    Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells.
    Yao TJ; Zhu JH; Peng DF; Cui Z; Zhang C; Lu PH
    Tumour Biol; 2015 Jul; 36(7):5641-8. PubMed ID: 25691251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
    Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
    Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
    Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
    Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.
    Kim ST; Jang HL; Lee SJ; Lee J; Choi YL; Kim KM; Cho J; Park SH; Park YS; Lim HY; Yashiro M; Kang WK; Park JO
    Mol Cancer Ther; 2014 Nov; 13(11):2527-36. PubMed ID: 25249557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
    Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
    Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
    Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
    J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNORD126 promotes HCC and CRC cell growth by activating the PI3K-AKT pathway through FGFR2.
    Fang X; Yang D; Luo H; Wu S; Dong W; Xiao J; Yuan S; Ni A; Zhang KJ; Liu XY; Chu L
    J Mol Cell Biol; 2017 Jun; 9(3):243-255. PubMed ID: 27913571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice].
    Wu T; Jiang X; Xu B; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1448-1456. PubMed ID: 33118510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.